Institut de Cancérologie de Strasbourg

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, intestinal disorder, neoplasm, rectal disorder, skin disorder	Recruiting	Phase 1 / Phase 2	2026-09-30		NCT06324357

Clinical trials